Show simple item record

dc.contributor.authorRafae, Abdul
dc.contributor.authorMalik, Mustafa N
dc.contributor.authorAbu Zar, Muhammad
dc.contributor.authorDurer, Seren
dc.contributor.authorDurer, Ceren
dc.date.accessioned2019-05-21T21:19:09Z
dc.date.available2019-05-21T21:19:09Z
dc.date.issued2018-08-15
dc.identifier.citationRafae A, Malik M N, Abu Zar M, et al. (August 15, 2018) An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring. Cureus 10(8): e3148. doi:10.7759/cureus.3148en_US
dc.identifier.issn2168-8184
dc.identifier.pmid30345204
dc.identifier.doi10.7759/cureus.3148
dc.identifier.urihttp://hdl.handle.net/10150/632345
dc.description.abstractLight chain multiple myeloma (LCMM) constitutes approximately 15% of patients with multiple myeloma (MM). It has a poorer prognosis when compared to immunoglobulin (Ig) G or IgA variant. We performed a comprehensive literature search on LCMM and identified a total of 390 articles. After a detailed screening, six studies involving a total of 1054 LCMM patients were included. A literature review revealed bone pain and renal failure as the most common initial sign and symptoms while extramedullary disease (EMD) was acquired later during the progression of the disease. Bortezomib has shown superior efficacy in LCMM patients over nonbortezomib regimens as demonstrated by better overall response rate (95.5% vs. 60%), progression-free survival (PFS) (25% vs. 9% at two years), and overall survival (OS) (24% vs. 9% at five years). Moreover, better PFS was seen, when bortezomib was used in combination with bendamustine compared to dexamethasone (95% vs. 25% at two years). Similarly, better OS (90% at two years) was observed with bortezomib in combination with bendamustine. Monitoring of disease should include scrum free light chain levels, as literature review revealed that serum assays were more sensitive in indicating the disease and predicting PFS and OS as compared to urine assays. We provide presentation patterns, clinical rarities, management strategies including their efficacy, and disease monitoring in patients with LCMM in our review paper.en_US
dc.language.isoenen_US
dc.publisherCUREUS INCen_US
dc.relation.urlhttps://www.cureus.com/articles/13514-an-overview-of-light-chain-multiple-myeloma-clinical-characteristics-and-rarities-management-strategies-and-disease-monitoringen_US
dc.rights© Copyright 2018 Rafae et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0.en_US
dc.subjectbortezomiben_US
dc.subjectlight chain only multiple myelomaen_US
dc.subjectsurvivalen_US
dc.titleAn Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoringen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Hematol & Oncolen_US
dc.identifier.journalCUREUSen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleCureus
refterms.dateFOA2019-05-21T21:19:10Z


Files in this item

Thumbnail
Name:
1553364020-20190323-2493-yc16mm.pdf
Size:
163.7Kb
Format:
PDF
Description:
Final Published version

This item appears in the following Collection(s)

Show simple item record